AJ91.DE • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold AJ91.DE in your mock portfolio yet.
With EPS at €1.15 and a PE ratio of 10.96, DocCheck AG appears reasonably valued and modestly profitable, suggesting no obvious red flags on earnings quality. However, without multi‑year revenue and margin data, it is difficult to conclude that the company is in a strong structural growth phase. Overall, the valuation looks fair to slightly conservative, but the growth profile is unclear from the provided data.
The stock is trading at €12.60, up 9.6% over the last month and above its 200‑day moving average of €11.80, which is typically a constructive medium‑term signal. However, the RSI at 31.98 is close to oversold territory, suggesting recent selling pressure or consolidation despite the monthly gain. Together, these mixed signals point to a technically balanced, rather than clearly bullish or bearish, setup.
Alternative data for DocCheck AG is largely flat to slightly positive: web traffic and app downloads are stable, job postings are inching higher, and most social channels show modest follower growth. These signals indicate a steady, but not rapidly accelerating, business and brand presence. There is no strong evidence of either a sharp inflection in demand or a deterioration in engagement.
Overall, DocCheck AG’s stock profile appears neutral: valuation is reasonable, technicals are mixed but not weak, and alternative data suggests a stable, moderately expanding business rather than a high‑growth story. Without clearer evidence of accelerating fundamentals, the setup leans more toward steady value than aggressive growth. The stock may appeal to investors seeking reasonably priced earnings with moderate, incremental improvement rather than a strong momentum play.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: